Asia-Pacific Cancer Therapy Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Market Overview

The Asia-Pacific cancer therapy market is expected to register a CAGR of 10.2% over the forecast period.

The COVID-19 pandemic disrupted routine care in many healthcare facilities and had an impact on healthcare systems all around the world, putting susceptible cancer patients in serious danger. The strict lockdowns and government regulations intended to slow down the spread of COVID-19 resulted in a decrease in therapy options for cancer patients. For instance, as per the study titled "Challenges and opportunities for ovarian cancer management in the epidemic of Covid-19: lessons learned from Wuhan, China" published in February 2021, treatment cancellation and delayed surgeries were challenging decisions. Ovarian cancer was identified as gynecologic cancer most affected by COVID-19, perhaps because of the frequent requirement for chemotherapy and ovarian debulking surgery. As a result, the pandemic might hurt the market. However, due to the rise in the incidence of cancers in the general population and fewer COVID-19 cases in the later stages of the pandemic, the market for treatments for cancer saw a noticeable increase in growth.

The Asia-Pacific cancer therapy market is expected to observe good growth owing to the rising prevalence of cancer, growing government initiatives for cancer awareness, and increasing patient assistance programs (PAPs). Lung, stomach, colorectum, liver, and esophagus are the most common types of cancer in Asia-Pacific region. For instance, as per the study titled "Burden of cancers in India - estimates of cancer crude incidence, YLLs, YLDs and DALYs for 2021 and 2025 based on National Cancer Registry Program" published in May 2022, the projected cancer burden in India for 2021 was 26.7 million Disability Adjusted Life Years (DALYs) and expected to increase to 29.8 million in 2025. Thus, the rising burden of cancers, helps the market to grow over the forecast period.

Furthermore, the advancements in the treatment of cancers with latest product approvals and launches drives the growth of the market. For instance, in August 2022, AstraZeneca India has received a Drugs Controller General of India (DCGI) approval to market its drug Lynparza (Olaparib) as a monotherapy for the adjuvant treatment of adult patients with BRCA-mutated HER2- negative high-risk early breast cancer. Therefore, owing to the aforementioned factors, the studied market is anticipated to witness growth over the analysis period.

However, the high cost of cancer therapies and fluctuation in reimbursement policies is likely to impede the market's growth.

Scope of the Report

As per the scope of the report, cancer therapies are drugs that block the growth and proliferation of cancer, by interfering with specific molecules, such as DNA or proteins, which are involved in the growth or expansion of cancerous cells. These therapies include surgery, radiation therapy, chemotherapy, immunotherapy, etc. The Asia-Pacific cancer therapy market is segmented by treatment type (chemotherapy, target therapy, immunotherapy, hormone therapy, and other treatment types), cancer type (blood cancer, breast cancer, prostate cancer, gastrointestinal cancer, gynecologic cancer, respiratory/lung cancer, and other cancer types), end user (hospitals, specialty clinics, radiation therapy center) and geography (China, Japan, India, Australia, South Korea and Rest of Asia-Pacific). The report offers the value (in USD million) for the above segments.

Report scope can be customized per your requirements. Click here.

Key Market Trends

Target Therapy is Expected to Show the Significant Growth Over the Forecast Period

Targeted therapy is a type of cancer treatment that targets the changes in cancer cells that help them grow, divide, and spread. The targeted therapy includes gene expression modulators, apoptosis inducers, angiogenesis inhibitors, signal transduction inhibitors, and toxin delivery molecules. The drugs for target therapy work by targeting the specific genes or proteins that are present in the cancer cells. Targeted therapy is attaining importance due to its specificity toward cancer cells while sparing toxicity to off-target cells.

The major factors driving the growth of the segment are an increase in R&D and the rising prevalence and incidence of various types of cancer across the globe. For instance, as per the 2022 updated report of Janssen, Asia Pacific hosts 50% of the world’s new cancer cases each year, and deaths caused by cancer in Asia are expected to increase by 36% by 2030. Also, Asia Pacific has the highest incidence of liver and stomach cancers, and prostate cancer is one of the leading male cancers in some Asian countries. Hence, increasing cancer will increase the demand for treatment options for cancers which will increase the market growth.

Furthermore, the new developments and approvals of the drugs under targeted therapy segment helps the market to grow. For instance, in August 2022, AstraZeneca’s Tagrisso (osimertinib) has been approved in Japan for the adjuvant treatment of patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after surgery.

Thus the above-mentioned factors are expected to drive the growth of the targeted therapy segment during the forecast period.

To understand key trends, Download Sample Report